Last February, the FDA nixed Vertex’s bid to expand cystic fibrosis med Kalydeco to patients with specific mutations in the CFTR gene. On Wednesday, though, the Cambridge drugmaker finally got what it ...
Vertex Pharmaceuticals Incorporated VRTX announced that the European Commission has approved label expansion of its combination regimen of Symkevi and Kalydeco. The regimen is now approved for ...
US regulators have expanded the label for Vertex’s cystic fibrosis drug, Kalydeco, extending its use to include children aged 12-24 months with certain genetic mutations. The FDA said Kalydeco ...
US regulators have expanded the label for Vertex’s cystic fibrosis drug, Kalydeco, extending its use to include children aged 12-24 months with certain genetic mutations. The FDA said Kalydeco ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback